Daiichi Sankyo, Ranbaxy to expand Hybrid Business Model in Romania

19 Apr 2012 Evaluate

Daiichi Sankyo and Ranbaxy Laboratories are planning to expand Hybrid Business Model in Romania. In this regard, Terapia Ranbaxy, a subsidiary of Ranbaxy in Romania, will launch Sevikar, a fixed dose combination of olmesartan medoxomil and amlodipine besylate tablets in Romania.

Sevikar will be available in three strengths of 5/20mg (amlodipine besylate 5mg, olmesartan medoxomil 20mg), 5/40mg (amlodipine besylate 5mg, olmesartan medoxomil 40mg) and 10/40mg (amlodipine besylate 10mg, olmesartan medoxomil 40mg). The product is expected to be included on the national lists of compensated drugs benefiting patients as it will be made available at an affordable price.

Ranbaxy Laboratories, India's largest pharmaceutical company, is an integrated, research based, international pharmaceutical company producing a wide range of quality, affordable generic medicines, trusted by healthcare professionals and patients across geographies.

Peers
Company Name CMP
Sun Pharma Inds. 1804.95
Dr. Reddys Lab 1275.05
Cipla 1520.55
Zydus Lifesciences 931.45
Lupin 2097.65
View more..
Register Now to get our Free Newsletter & much more!

© 2025 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt. Ltd.

×